A review of therapeutic uses of mirtazapine in psychiatric and medical conditions

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 15, Issue 5, 2013, Pages

  Alam, Abdulkader ^a   Voronovich, Zoya ^b   Carley, Joseph A ^c  

^a Departments of Psychiatry and Medicine   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; FLUOXETINE; IBUPROFEN; MEFLOQUINE; MIRTAZAPINE; MODAFINIL; NORTRIPTYLINE; PAROXETINE; PERICIAZINE; PLACEBO; PRIMIDONE; PROPRANOLOL; REBOXETINE; SERTRALINE; VENLAFAXINE;

ADDICTION; ADJUVANT THERAPY; AGITATED DEPRESSION; ALCOHOLISM; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; APPETITE DISORDER; CANCER PAIN; COMORBIDITY; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; GERIATRIC DEPRESSION; HUMAN; HYPERPHAGIA; INSOMNIA; INVOLUTIONAL DEPRESSION; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; MENTAL DISEASE; METHAMPHETAMINE DEPENDENCE; MIXED ANXIETY AND DEPRESSION; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; POSTMYOCARDIAL INFARCTION DEPRESSION; POSTSTROKE DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSE TIME; REVIEW; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDERED BREATHING; SOMNOLENCE; SUBSTANCE ABUSE; TABLET; TEMPORAL LOBE EPILEPSY; TENSION HEADACHE; TREATMENT RESISTANT DEPRESSION; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84888123801     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.13r01525     Document Type: Review

References (107)

1. Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig. 1998;15(1):45-55. PubMed doi:10.2165/00044011-199815010-00006 Show Abstract Show Abstract
2. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10(suppl 4):19-23. PubMed doi:10.1097/00004850-199512004-00004 Show Abstract Show Abstract
3. Montgomery S, Schutte A, Reimitz P. Mirtazapine and onset of action of antidepressant activity. Int J Neuropsychopharmacol. 2000;3:249.
4. Behnke K, Søgaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol. 2003;23(4):358-364. PubMed doi:10.1097/01.jcp.0000085408.08426.05 Show Abstract Show Abstract
5. de Boer T, Ruigt GS. The selective [alpha]2-adrenoceptor antagonist mirtazapine (org 3770) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission. CNS Drugs. 1995;4(suppl 1):29-38. doi:10.2165/00023210-199500041-00006
6. De Montigny C, Haddjeri N, Mongeau R, et al. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs. 1995;4(suppl 1):13-17. doi:10.2165/00023210-199500041-00004
7. Bengtsson HJ, Kele J, Johansson J, et al. Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(4-5):406-412. PubMed doi:10.1007/s002100000294 Show Abstract Show Abstract
8. Barkin RL, Schwer WA, Barkin SJ. Recognition and management of depression in primary care: a focus on the elderly: a pharmacotherapeutic overview of the selection process among the traditional and new antidepressants. Am J Ther. 2000;7(3):205-226. PubMed doi:10.1097/00045391-200007030-00008 Show Abstract Show Abstract
9. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(suppl 4):19-25. PubMed Show Abstract Show Abstract
10. Benkert O, Szegedi A, Philipp M, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol. 2006;26(1):75-78. PubMed doi:10.1097/01.jcp.0000194622.99986.d6 Show Abstract Show Abstract
11. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38(6):461-474. PubMed doi:10.2165/00003088-200038060-00001 Show Abstract Show Abstract
12. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56(11):519-525. PubMed Show Abstract Show Abstract
13. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Human Psychopharmacology: Clinical and Experimental. 1995;10(3):173-180. doi:10.1002/hup.470100302
14. Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol. 1996;10(3):235-240. PubMed doi:10.1177/026988119601000310 Show Abstract Show Abstract
15. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Human Psychopharmacology: Clinical and Experimental. 1995;10(S2):S125-S133. doi:10.1002/hup.470100807
16. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995;10(1):3-9. PubMed doi:10.1097/00004850-199503000-00001 Show Abstract Show Abstract
17. Stahl S, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand suppl. 1997;391(s391):22-30. PubMed doi:10.1111/j.1600-0447.1997.tb05955.x Show Abstract Show Abstract
18. Wheatley DP, van Moffaert M, Timmerman L, et al; Mirtazapine-Fluoxetine Study Group. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry. 1998;59(6):306-312. PubMed doi:10.4088/JCP.v59n0606 Show Abstract Show Abstract
19. Leinonen E, Skarstein J, Behnke K, et al; Nordic Antidepressant Study Group. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol. 1999;14(6):329-337. PubMed doi:10.1097/00004850-199911000-00002 Show Abstract Show Abstract
20. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61(9):656-663. PubMed doi:10.4088/JCP.v61n0911 Show Abstract Show Abstract
21. Rodriguez AG, Ferrer CG, Odriozola VN. Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder. Clin Med Insights Therapeutics. 2012;4:57-63. doi:10.4137/CMT.S7632
22. Kim JE, Yoon SJ, Kim J, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract. 2011;65(3):323-329. PubMed doi:10.1111/j.1742-1241.2010.02624.x Show Abstract Show Abstract
23. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189-198. PubMed doi:10.1097/YIC.0b013e328330adb2 Show Abstract Show Abstract
24. Szegedi A, Müller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64(4):413-420. PubMed doi:10.4088/JCP.v64n0410 Show Abstract Show Abstract
25. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry. 2001;62(5):358-361. PubMed doi:10.4088/JCP.v62n0509 Show Abstract Show Abstract
26. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol. 2003;18(3):133-141. PubMed Show Abstract Show Abstract
27. Guelfi JD, Ansseau M, Timmerman L, et al; Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21(4):425-431. PubMed doi:10.1097/00004714-200108000-00010 Show Abstract Show Abstract
28. Thase ME, Nierenberg AA, Keller MB, et al; Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry. 2001;62(10):782-788. PubMed doi:10.4088/JCP.v62n1006 Show Abstract Show Abstract
29. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998;13(2):63-73. PubMed doi:10.1097/00004850-199803000-00002 Show Abstract Show Abstract
30. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002;51(2):183-188. PubMed doi:10.1016/S0006-3223(01)01262-8 Show Abstract Show Abstract
31. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163(7):1161-1172. PubMed doi:10.1176/appi.ajp.163.7.1161 Show Abstract Show Abstract
32. Hirschfeld RMA. The use of mirtazapine in difficult-to-treat patient populations. Hum Psychopharmacol. 2002;17(suppl 1):S33-S36. PubMed doi:10.1002/hup.387 Show Abstract Show Abstract
33. Versiani M, Moreno R, Ramakers-van Moorsel CJA, et al; Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137-146. PubMed doi:10.2165/00023210-200519020-00004 Show Abstract Show Abstract
34. Morris DW, Budhwar N, Husain M, et al. Depression treatment in patients with general medical conditions: results from the CO-MED trial. Ann Fam Med. 2012;10(1):23-33. PubMed doi:10.1370/afm.1316 Show Abstract Show Abstract
35. Kang E-H, Lee IS, Chung SK, et al. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial. Psychiatry Res. 2009;169(2):118-123. PubMed doi:10.1016/j.psychres.2008.06.021 Show Abstract Show Abstract
36. Dowlati Y, Herrmann N, Swardfager WL, et al. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can J Psychiatry. 2010;55(2):91-99. PubMed Show Abstract Show Abstract
37. de Jonge P, Honig A, van Melle JP, et al; MIND-IT Investigators. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry. 2007;164(9):1371-1378. PubMed doi:10.1176/appi.ajp.2007.06091492 Show Abstract Show Abstract
38. Honig A, Kuyper AM, Schene AH, et al; MIND-IT investigators. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606-613. PubMed doi:10.1097/PSY.0b013e31814b260d Show Abstract Show Abstract
39. Tulner DM, Smith OR, Schins A, et al. Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: data from the MIND-IT. Neuropsychobiology. 2011;63(3):169-176. PubMed doi:10.1159/000321624 Show Abstract Show Abstract
40. Niedermaier N, Bohrer E, Schulte K, et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry. 2004;65(12):1619-1623. PubMed doi:10.4088/JCP.v65n1206 Show Abstract Show Abstract
41. Kühn K-U, Quednow BB, Thiel M, et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav. 2003;4(6):674-679. PubMed doi:10.1016/j.yebeh.2003.08.009 Show Abstract Show Abstract
42. Altintoprak AE, Zorlu N, Coskunol H, et al. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. Hum Psychopharmacol. 2008;23(4):313-319. PubMed doi:10.1002/hup.935 Show Abstract Show Abstract
43. Afshar M, Knapp CM, Sarid-Segal O, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse. 2012;38(2):181-186. PubMed doi:10.3109/00952990.2011.644002 Show Abstract Show Abstract
44. Varia I, Venkataraman S, Hellegers C, et al. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. Psychopharmacol Bull. 2007;40(1):47-56. PubMed Show Abstract Show Abstract
45. Roose SP, Nelson JC, Salzman C, et al; Mirtazapine in the Nursing Home Study Group. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Curr Med Res Opin. 2003;19(8):737-746. PubMed doi:10.1185/030079903125002441 Show Abstract Show Abstract
46. Schatzberg AF, Kremer C, Rodrigues HE, et al; Mirtazapine vs Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10(5):541-550. PubMed Show Abstract Show Abstract
47. Høyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996;93(3):184-190. PubMed doi:10.1111/j.1600-0447.1996.tb10629.x Show Abstract Show Abstract
48. Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403-411. PubMed doi:10.1016/S0140-6736(11)60830-1 Show Abstract Show Abstract
49. Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer's disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat. 2008;4(5):963-966. PubMed doi:10.2147/NDT.S3201 Show Abstract Show Abstract
50. Liappas J, Paparrigopoulos T, Tzavellas E, et al. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord. 2003;76(1-3):279-284. PubMed doi:10.1016/S0165-0327(02)00094-0 Show Abstract Show Abstract
51. Liappas J, Paparrigopoulos T, Malitas P, et al. Mirtazapine improves alcohol detoxification. J Psychopharmacol. 2004;18(1):88-93. PubMed doi:10.1177/0269881104040241 Show Abstract Show Abstract
52. Liappas J, Paparrigopoulos T, Tzavellas E, et al. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):55-60. PubMed doi:10.1016/j.pnpbp.2004.10.005 Show Abstract Show Abstract
53. Colfax GN, Santos GM, Das M, et al. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68(11):1168-1175. PubMed doi:10.1001/archgenpsychiatry.2011.124 Show Abstract Show Abstract
54. Cruickshank CC, Montebello ME, Dyer KR, et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev. 2008;27(3):326-333. PubMed doi:10.1080/09595230801935672 Show Abstract Show Abstract
55. McGregor C, Srisurapanont M, Mitchell A, et al. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat. 2008;35(3):334-342. PubMed doi:10.1016/j.jsat.2007.12.003 Show Abstract Show Abstract
56. Boshuisen ML, Slaap BR, Vester-Blokland ED, et al. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol. 2001;16(6):363-368. PubMed doi:10.1097/00004850-200111000-00008 Show Abstract Show Abstract
57. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001;34(10):1303-1307. PubMed doi:10.1590/S0100-879X2001001000010 Show Abstract Show Abstract
58. Sarchiapone M, Amore M, De Risio S, et al. Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol. 2003;18(1):35-38. PubMed doi:10.1097/00004850-200301000-00006 Show Abstract Show Abstract
59. Bahk W-M, Pae CU, Tsoh J, et al. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum Psychopharmacol. 2002;17(7):341-344. PubMed doi:10.1002/hup.426 Show Abstract Show Abstract
60. Davidson JRT, Weisler RH, Butterfield MI, et al. Mirtazapine vs placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003;53(2):188-191. PubMed doi:10.1016/S0006-3223(02)01411-7 Show Abstract Show Abstract
61. Chung MY, Min KH, Jun YJ, et al. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol. 2004;19(7):489-494. PubMed doi:10.1002/hup.615 Show Abstract Show Abstract
62. Seo H-J, Jung Y-E, Bank W-M, et al. A comparison of mirtazapine and paroxetine for the treatment of patients with posttraumatic stress disorder: a randomized open-label trial. Clin Psychopharmacol Neurosci. 2010;8(2):84-89.
63. Alderman CP, Condon JT, Gilbert AL. An open-label study of mirtazapine as treatment for combat-related PTSD. Ann Pharmacother. 2009;43(7):1220-1226. PubMed doi:10.1345/aph.1M009 Show Abstract Show Abstract
64. Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66(4):515-520. PubMed doi:10.4088/JCP.v66n0415 Show Abstract Show Abstract
65. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004;65(10):1394-1399. PubMed doi:10.4088/JCP.v65n1015 Show Abstract Show Abstract
66. Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol. 2005;19(5):483-487. PubMed doi:10.1177/0269881105056527 Show Abstract Show Abstract
67. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25(6):580-583. PubMed doi:10.1097/01.jcp.0000186871.04984.8d Show Abstract Show Abstract
68. Van Veen JF, Van Vliet IM, Westenberg HGM. Mirtazapine in social anxiety disorder: a pilot study. Int Clin Psychopharmacol. 2002;17(6):315-317. PubMed doi:10.1097/00004850-200211000-00008 Show Abstract Show Abstract
69. Schutters SIJ, Van Megen HJGM, Van Veen JF, et al. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010;25(5):302-304. PubMed doi:10.1097/YIC.0b013e32833a4d71 Show Abstract Show Abstract
70. Schutters SI, van Megen HJ, Van Veen JF, et al. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol. 2011;26(1):72-76. PubMed doi:10.1002/hup.1165 Show Abstract Show Abstract
71. Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992;5(1):49-73. PubMed Show Abstract Show Abstract
72. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306(5700):1380-1383. PubMed doi:10.1126/science.1103492 Show Abstract Show Abstract
73. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol. 2009;66(2):255-258. PubMed doi:10.1001/archneurol.2008.557 Show Abstract Show Abstract
74. Moenster RP, Jett RA. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm. 2012;69(6):496-498. PubMed doi:10.2146/ajhp110392 Show Abstract Show Abstract
75. Lima MA, Auriel E, Wüthrich C, et al. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis. 2005;41(3):417-419. PubMed doi:10.1086/431769 Show Abstract Show Abstract
76. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438-446. PubMed doi:10.1016/S1474-4422(10)70028-4 Show Abstract Show Abstract
77. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology. 1999;53(5):1154. PubMed doi:10.1212/WNL.53.5.1154-a Show Abstract Show Abstract
78. Pahwa R, Lyons KE. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov Disord. 2003;18(5):584-587. PubMed doi:10.1002/mds.10371 Show Abstract Show Abstract
79. Uccellini D, Grampa G, La Spina I, et al. Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study. Neuropsychiatr Dis Treat. 2006;2(1):95-100. PubMed Show Abstract Show Abstract
80. Deuschl G, Raethjen J, Hellriegel H, et al. Treatment of patients with essential tremor. Lancet Neurol. 2011;10(2):148-161. PubMed doi:10.1016/S1474-4422(10)70322-7 Show Abstract Show Abstract
81. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology. 2004;62(10):1706-1711. PubMed doi:10.1212/01.WNL.0000127282.90920.8C Show Abstract Show Abstract
82. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996;61(3):285-290. PubMed doi:10.1136/jnnp.61.3.285 Show Abstract Show Abstract
83. Bendtsen L, Buchgreitz L, Ashina S, et al. Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headache. Eur J Neurol. 2007;14(2):187-193. PubMed doi:10.1111/j.1468-1331.2006.01607.x Show Abstract Show Abstract
84. Arnold P, Vuadens P, Kuntzer T, et al. Mirtazapine decreases the pain feeling in healthy participants. Clin J Pain. 2008;24(2):116-119. PubMed doi:10.1097/AJP.0b013e318159f94a Show Abstract Show Abstract
85. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002;23(5):442-447. PubMed doi:10.1016/S0885-3924(02)00381-0 Show Abstract Show Abstract
86. Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry. 2004;37(4):168-170. PubMed doi:10.1055/s-2004-827172 Show Abstract Show Abstract
87. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5(5):389-402. doi:10.2165/00023210-199605050-00007
88. Sussman N, Ginsberg DL. Weight effects of nefazodone, bupropion, mirtazapine, and venlafaxine: a review of available evidence. Prim Psychiatry. 2000;7:33-48.
89. Riechelmann RP, Burman D, Tannock IF, et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010;27(2):106-110. PubMed doi:10.1177/1049909109345685 Show Abstract Show Abstract
90. Boas S, McColley S, Danduran M, et al. The role of mirtazapine as an appetite stimulant in malnourished individuals with CF. Pediatr Pulmonol. 2000;30:325-326.
91. Sykes R, Kittel F, Marcus M, et al. Mirtazapine for appetite stimulation in children with cystic fibrosis. Pediatr Pulmonol. 2006;59:389-390.
92. Chinuck RS, Fortnum H, Baldwin DR. Appetite stimulants in cystic fibrosis: a systematic review. J Hum Nutr Diet. 2007;20(6):526-537. PubMed doi:10.1111/j.1365-277X.2007.00824.x Show Abstract Show Abstract
93. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006;29(1):170-171. PubMed doi:10.2337/diacare.29.1.170 Show Abstract Show Abstract
94. Stimmel GL, Sussman N, Wingard P. Mirtazapine safety and tolerability: analysis of the clinical trials database. Prim Psychiatry. 1997;4:82-90.
95. Radhakishun FS, van den Bos J, van der Heijden BC, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol. 2000;20(5):531-537. PubMed doi:10.1097/00004714-200010000-00006 Show Abstract Show Abstract
96. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep. 2002;25(6):677-679. PubMed Show Abstract Show Abstract
97. Winokur A, DeMartinis NA 3rd, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64(10):1224-1229. PubMed doi:10.4088/JCP.v64n1013 Show Abstract Show Abstract
98. Carley DW, Olopade C, Ruigt GS, et al. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep. 2007;30(1):35-41. PubMed Show Abstract Show Abstract
99. Marshall NS, Yee BJ, Desai AV, et al. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep. 2008;31(6):824-831. PubMed Show Abstract Show Abstract
100. Saks BR. Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient: a report of 7 cases. Arch Women Ment Health. 2001;3(4):165-170. doi:10.1007/s007370170014
101. Rohde A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet. 2003;268(3):219-221. PubMed doi:10.1007/s00404-003-0502-0 Show Abstract Show Abstract
102. Chen CC, Lin CS, Ko YP, et al. Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesth Analg. 2008;106(1):109-113. PubMed doi:10.1213/01.ane.0000289636.09841.bc Show Abstract Show Abstract
103. Chang F-L, Ho S-T, Sheen MJ. Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery. Anaesthesia. 2010;65(12):1206-1211. PubMed doi:10.1111/j.1365-2044.2010.06561.x Show Abstract Show Abstract
104. Saiz-Ruiz J, Montes JM, Ibáñez A, et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Hum Psychopharmacol. 2005;20(6):435-440. PubMed doi:10.1002/hup.706 Show Abstract Show Abstract
105. Michelson D, Kociban K, Tamura R, et al. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res. 2002;36(3):147-152. PubMed doi:10.1016/S0022-3956(01)00060-7 Show Abstract Show Abstract
106. Schutters SI, van Megen HJ, Van Veen JF, et al. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol. 2011;26(1):72-76. PubMed doi:10.1002/hup.1165 Show Abstract Show Abstract
107. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J Clin Psychopharmacol. 2003;23(5):467-470. PubMed doi:10.1097/01.jcp.0000088904.24613.e4 Show Abstract Show Abstract